Volltext
Rosuvastatin (Crestor) and March 2012 Page 1 of 1 risk of gynaecomastia
Doc.Ref.: CMDh/PhVWP/041/2012 March 2012, Rev1
SUMMARY OF PRODUCT CHARACTERISTICS Section 4.8 Undesirable effect
Reproductive system and breast disorders
… gynaecomastia Frequency
- Very rare
PACKAGE LEAFLET
Section 4 ‘Possible side effects’
Gynecomastia (breast enlargement in men) - Very rare
ÄHNLICHE DOKUMENTE
Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such
In an epidemiological study using a UK database, the risk of VTE in association with tibolone was lower than the risk associated with conventional HRT, but only a small proportion
There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with [drug name]. The mechanism by which [drug
An initial dose of 8 mg (4 drops) daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual
Once asthma symptoms are controlled, consideration should be given to gradually reducing the dose of LABA; regular review of patients as treatment is stepped down is important;..
Acute poisoning was observed after significant accidental consumption, with nausea, vomiting, abdominal pain, and headache, vertigo, feeling hot / flushing, convulsions,
Some cases of severe liver reactions, including cases with fatal outcome or requiring liver transplant, have been reported in both children and adults treated with
The occurrence of (multiple) meningiomas has been reported in association with longer term use (years) of cyproteronacetate at doses of 25mg/day and above. If a patient treated
